Navigation Links
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results

First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline

BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced the positive clinical results of its Phase IIa Alkaline Phosphatase (AP) trial for patients with ulcerative colitis, a chronic and relapsing inflammatory bowel disease affecting the colon.

In this recent trial, AP was used in the treatment of 21 hospitalised patients suffering from moderate to severe ulcerative colitis, who had failed to show improvement using existing treatments of steroids and immunosuppressants. The AP therapy was administered through a duodenal drip at a dose of 10mg AP per day.

In the trial, patients showed clinically relevant improvement after the seven day treatment period, in the two main clinical parameters (Truelove-Witts and Mayo scores) measured three weeks after starting the AP trial.

Patient response rates after three weeks were 63% on the Truelove-Witts score and 47% on the Mayo score. Complete remission after three weeks was reached by 21% of patients on the Truelove-Witts score and by 5% of patients on the Mayo score. After 63 days, 79% of patients showed a response and 26% of patients were in complete remission according to the Truelove-Witts score. No serious adverse effects or treatment-related withdrawals were reported.

AP is a unique therapy for ulcerative colitis based on the dephosphorylation and detoxification of a group of bacterial endotoxins called lipopolysaccharides, which can cause inflammation in the colon. AM-Pharma's patented AP treatment has already shown positive results in trials for treatment of acute renal failure and sepsis.

Bart Wuurman, CEO commented: "It's fantastic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/22/2014)... , July 22, 2014  According to the American ... children spend on digital devices. An AOA survey reports ... 10 and 17 estimate they use an electronic device ... separate AOA survey of parents revealed that only 40 ... device for that same amount of time. Eye doctors ...
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: VER) and ... proof-of-concept (POC) for CCP-08, the third programme to ... cold collaboration. Under this collaboration, POC requires the ... human pilot comparative study against an immediate release ... Vernalis will make a milestone payment to Tris. ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... 29, 2012  MedImmune today announced that the U.S. ... Quadrivalent (Influenza Vaccine Live, Intranasal) for prevention of ... the second quarter of last year.  FluMist Quadrivalent ... the FDA. All other currently available ...
... 29, 2012 Accuray Incorporated (Nasdaq: ... it has received the NorthFace ScoreBoard Award(SM) ... (Omega) in recognition of achieving excellence in customer service and ... customer satisfaction, Accuray is the first organization also to qualify ...
Cached Medicine Technology:MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 3Accuray Recognized for Delivering 'World-Class' Customer Service 2Accuray Recognized for Delivering 'World-Class' Customer Service 3Accuray Recognized for Delivering 'World-Class' Customer Service 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Beryl ... and third annual Institute Scholar Program. These offerings reinforce ... the patient experience in healthcare and the need for ... The grant and scholar programs are intended ... , Value of focusing on the patient experience ...
(Date:7/22/2014)... July 22, 2014 The market for ... past few years, owing to novel medical indications created ... in the aging societies where physical appearance is extremely ... one player, current competitors, new companies and technologies are ... biosimilar BoNTs will put the price of 1st-gen products ...
(Date:7/22/2014)... CarePoint Health is pleased to announce that ... of the medical staff at Bayonne Medical Center. The election ... as voted on by the physicians on staff. The office ... relation to the administration at Bayonne Medical Center. Dr. Levine ... work to make the Medical Center the best it can ...
(Date:7/22/2014)... The Middle East Drilling fluid and Completion fluid ... fluid market in Middle East with analysis and forecast of ... East is estimated to grow from around $560 million in ... 5.7%, for the given period. , Browse through the TOC ... report, to get an idea of the in-depth analysis provided. ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Over ... in almost every sphere of human anatomy. In ... forth advancements that rendered the possibility of deploying ... including blood and tissues, in order to detect ... congenital abnormality. Essentially, In-vitro Diagnostics (IVD) have earned ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4
... The medical community has repeatedly warned against plying young children with ... parents seem to care . Certainly not in Australia. ... extractions, dentists in that country say. ,In the ... but to remove all 20 baby teeth. ,"It's ...
... long ago there was a theory doing the rounds that ... autistic individual. This theory was not well received and ... prompted the proponents of the theory to associate the schemingly ... autism? ,Autism is a developmental disability that affects ...
... way for 70-year-old Hakimuddin of Orissa and his three ... after the impoverished man wrote to India's president ... district collector of Bhadrak in Orissa constituted a team ... on the condition of the poor family in Kamalpur ...
... common genetic variation on chromosome 9p21 is linked to a ... new international research study . The findings are published today ... an upcoming printed edition of the journal. ,Researchers ... of suffering a heart attack (myocardial infarction) and a 2.02-fold ...
... (CE-US) after a liver transplant is highly accurate in ... to a recent study. ,The study consisted ... exam after developing fluid in the abdomen and/or unclear ... serious complication in the early post transplant period, caused ...
... University researchers seem to know what makes certain babies prone ... Edinburgh University and the Royal Hospital for Sick Children in ... premature and small babies which expose them to risks of ... of the maternal and child health sciences division, are team ...
Cached Medicine News:Health News:Experts Call for Warning Lables on Fruit Juice to Save Kids' Teeth 2Health News:Diet for Autism 2Health News:Diet for Autism 3Health News:Disabled Orissa Brothers Lives Saved by Timely Intervention 2Health News:Genetic Variation is Linked to Substantial Risk in Heart Attack 2
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes....
... Perfect Single Vac Manifold is ... plate in 30 minutes; the ... "open/closed" switch and a vacuum ... operation. contains vacuum chamber, on/off ...
... automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology ... ... ... ...
Plastic Tray Type Vacuum Manifold...
Medicine Products: